CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gyre Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gyre Therapeutics Inc
12770 High Bluff Drive, Suite 150
Phone: (619) 949-3681p:619 949-3681 SAN DIEGO, CA  92130  United States Ticker: GYREGYRE

Business Summary
Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The Company is focused on organ fibrosis and inflammatory diseases. The Company is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board YingLuo 57 10/30/2023 12/26/2022
President, Director SongjiangMa 68 10/30/2023 10/30/2023
Chief Executive Officer, Director HanYing 59 1/15/2024 10/30/2023
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Beijing Continent Pharmaceuticals Co Ltd Room 507-509, Tower 3, Wangjing Soho Tower Beijing BEJ China
GNI Group Ltd 3F, Nihonbashi-Honcho YS Bldg CHUO-KU TKY Japan

Business Names
Business Name
Aaring Limited
Beijing Continent Biomedical Technology Co., Ltd. People’s Republic of China
Beijing Continent Pharmaceuticals Co Ltd
10 additional Business Names available in full report.

General Information
Number of Employees: 7 (As of 12/31/2022)
Outstanding Shares: 76,569,069 (As of 10/31/2023)
Shareholders: 65
Stock Exchange: NASD
Federal Tax Id: 562020050
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024